The influence of growth and sex hormones on risk of alzheimer’s disease: a mendelian randomization study

Abstract

<p>Alzheimer’s disease is more prevalent in women, possibly due to sex or growth hormones but existing evidence is inconclusive. We investigated whether genetically predicted sex and growth hormones are associated with risk of Alzheimer’s disease. Genetic variants strongly and independently predicting insulin-like growth factor 1 (IGF-1), testosterone and sex hormone-binding globulin (SHBG) were obtained from large, published genome wide associations studies (GWAS) and applied to GWAS of Alzheimer’s disease based on clinical diagnosis (cases = 21,982, control = 41,944) from the International Genomics of Alzheimer’s Project and the UK Biobank parental (maternal cases = 27,696; paternal cases = 14,338) and siblings’ diagnosis (cases = 2,171) as proxy cases. Published GWAS summary statistics were used in our analyses. Estimates were obtained from inverse variance weighting with sensitivity analysis (i.e., MR-Egger, weighted median and MR-PRESSO). Multivariable analyses adjusted for pleiotropic effects and possible sources of selection bias were also performed. Genetically predicted higher total testosterone may reduce the risk of paternal Alzheimer’s disease (odds ratio (OR) 0.86, 95% confidence interval (CI) 0.76 to 0.97, per SD increase in testosterone) and in meta-analysis for women (OR 0.92, 95% CI 0.87, 0.98) with directionally similar results from other analyses. SHBG were not associated with Alzheimer’s disease. IGF-1 in women was inversely associated with risk of clinical Alzheimer’s disease in sensitivity analysis but not in the main analysis. These results suggest genetically predicted higher total testosterone may lower risk of Alzheimer’s disease. The role of testosterone and the immune system in Alzheimer’s disease could be further investigated.<br></p>